Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference GlobeNewswire December 01, 2025 – Seeking Alignment with European Medicines Agency (EMA) at February 2026 Meeting –– Actively Evaluating Strategy Across DLB and Alzheimer's Disease – PURCHASE, N.Y., Dec. 01, 2025 (GLOBE NEWSWIRE) — Cognition […]